Free Trial
NASDAQ:HPTX

(HPTX) (HPTX) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
N/A
Average Volume
786,899 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
HPTX stock logo

About (HPTX) Stock (NASDAQ:HPTX)

Horizon Therapeutics, Inc., formerly Hyperion Therapeutics, Inc., is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company's products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder. The Company's products are used to lower ammonia in the blood. RAVICTI is used to treat urea cycle disorders (UCD). BUPHENYL is indicated as an adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). The Company sells BUPHENYL under the brand name AMMONAPS in Europe and the Middle East.

HPTX Stock News Headlines

ESA confirms cancellation of E3 2023
These Are the 12 Best Picnic Spots in Dallas
This Week's Dallas Area Events
See More Headlines
Receive HPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (HPTX) and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/26/2015
Today
5/26/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HPTX
CUSIP
44915N10
Web
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

HPTX Stock Analysis - Frequently Asked Questions

How were (HPTX)'s earnings last quarter?

(HPTX) (NASDAQ:HPTX) posted its earnings results on Thursday, February, 26th. The biopharmaceutical company reported $0.47 EPS for the quarter, topping analysts' consensus estimates of ($0.20) by $0.67. The biopharmaceutical company had revenue of $30.80 million for the quarter, compared to analyst estimates of $24.60 million. (HPTX)'s quarterly revenue was up 65.6% compared to the same quarter last year.

What other stocks do shareholders of (HPTX) own?
This page (NASDAQ:HPTX) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners